What are the merger inhibitors?
Mushroom inhibitors are drugs that are designed to prevent the virus of human immunodeficiency (HIV) entering cells. The aim of this drug class is basically aiming the virus at the pass and attacking it before it gets a chance to attack the body. These drugs, also known as inhibitors, are designed for use as part of HIV combined therapy, which means that they must be used with other antiretroviral drugs to be effective.
The way inhibitors of fusion works is quite simple. In order to replicate in the body, HIV must join human cells and carry their normal routine, which forces them to create clones of the virus instead of fulfilling their normal function. In order to connect to the cells, HIV must form bonds with proteins in cells. The virus has a number of proteins that target a specific spot on potential host cells. The fusion inhibitors disrupt these proteins, making the virus impossible to attach to another cell.
Some fusion inhibitors simply connect to proteins, cOJ blocks the potential for binding with human cells. Others mutate proteins, which differ enough to become broken. The development of this class of drugs was only possible by extensive research by HIV, which allowed drug companies to identify proteins involved in the connection process. Preventing connections from the merger inhibitors reduce the overall viral load, making HIV more difficult to develop on a full AIDS.
Since 2008, two fusion inhibitors have been approved for use in patients. Both drugs were recommended for use in patients who have already tried other drugs in combined therapy and provided some hope to patients who found other drugs ineffective against the virus. Inhibitors of merger are currently not recommended in patients who are currently starting combined therapy for HIV treatment, although this may change because multiple fusion inhibitors are entering the market.
as well as other medicines used in the treatment of HIVThey represent a lifelong commitment inhibitors. Patients must consistently take combined therapy to suppress HIV in their bodies. Long -term combined therapy can be very expensive, especially with newer drugs that tend to consider the insurance company "experimental", allowing them to eliminate coverage. Combined therapy with new HIV/AIDS drugs is only available in the industrial world, because the cost of such drugs and the need for consistent regime is unbearable in developing countries.